A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Belantamab mafodotin (Primary) ; Dexamethasone; Dostarlimab; Feladilimab; GSK 3174998; Isatuximab; Lenalidomide; Nirogacestat; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DREAMM5
- Sponsors GSK
- 21 Jan 2025 New trial record
- 17 Jun 2022 Results (n=10; data cut-off Nov 15, 2021) assessing efficacy and safety (synergistic effects) of low dose belantamab mafodotin in combination with nirogacestat in patients with relapsed/refractory multiple myeloma, presented at the 27th Congress of the European Haematology Association.
- 08 Dec 2020 Trial design presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.